The role of stem cell transplantation in the management of relapsed follicular lymphoma in the era of targeted therapies

Jane E. Norman*, Harry C. Schouten, Peter Dreger, Stephen P. Robinson

*Corresponding author for this work

Research output: Contribution to journal(Systematic) Review article peer-review

9 Citations (Web of Science)

Abstract

Patients with relapsed follicular lymphoma (FL) following first-line therapy have an increasing number of management strategies ranging from observation through to stem cell transplantation. There has been an exciting expansion in novel agents to treat FL, but at present there is not a universally accepted standard of care in the relapse setting. Decision-making can be difficult for the clinician as there is a paucity of data to compare the various relapse therapies available. This review will discuss conventional therapy for relapsed FL, consider the use of novel agents and explore the role and timing of autologous and allogeneic stem cell transplantation.

Original languageEnglish
Pages (from-to)787-797
Number of pages11
JournalBone Marrow Transplantation
Volume54
Issue number6
DOIs
Publication statusPublished - Jun 2019

Keywords

  • NON-HODGKIN-LYMPHOMA
  • TERM-FOLLOW-UP
  • BONE-MARROW-TRANSPLANTATION
  • PROGRESSION-FREE SURVIVAL
  • HIGH-DOSE THERAPY
  • CHRONIC LYMPHOCYTIC-LEUKEMIA
  • CHIMERIC-ANTIGEN-RECEPTOR
  • LOW-GRADE
  • OPEN-LABEL
  • PHASE-II

Cite this